Valores de referencia para proteína transportadora de hormona de crecimiento en una población pediátrica normal

C, Teresa E Salazar; Mericq, Maria Veronica; F, Marcela Espinoza; Íñiguez, Germán; Sq, Pilar Carvallo de; G, Fernando Cassorla

doi:10.4067/s0034-98872001000400006

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this reason, based on the genetic background of the Chilean population, the establishment of local RIs is relevant. Previous studies in the Chilean population have focused mainly on obtaining RIs for adults in haematological parameters or in the hormonal study in paediatric groups [13] [14] [15] . Consequently, the objective of this study is to establish RIs for various biochemical markers of routine obtained from apparently healthy subjects of La Araucanía region in Southern Chile, treated at the Clinical Laboratory, Universidad Católica de Temuco.…”

Section: Introductionmentioning

confidence: 99%

Reference intervals of biochemical parameters in Chilean adults

Letelier,

Acuña,

Garrido

et al. 2024

J Med Biochemistry

View full text Add to dashboard Cite

Background. Establishing reference intervals (RIs) in clinical laboratories is essential, as these can vary due to inter-individual variability as well as the analytical methods used. The purpose of this study was to determine RIs for various biochemical markers in the Chilean adult population. Methods. A sample of 1,143 individuals was selected from the UC Temuco Clinical Laboratory database, which were analysed by sex. The Tukey Fence method was used to detect outliers and the RIss were established using the non-parametric method recommended by the IFCC. Results. The RIs obtained for the female sex were: Urea 14.9-44.2 mg/dL, AST 11.8-41.4 U/L, ALT 7.9-67.2 U/L, Alkaline Phosphatase 50-150 U/L, Total Bilirubin 0.206-1.017 mg/dL, Direct Bilirubin 0.088-0.287 mg/dL, Uric Acid 2.5-6.1 mg/dl and Total Proteins 6.63-8.03 g/L and for males: Urea 19.7-49.1 mg/dL, AST 13.2-48.2 U/L, ALT 11-114.3 U/L, Alkaline Phosphatase 56-140 U/L, Total Bilirubin 0.268-1.408 mg/dL, Direct Bilirubin 0.109-0.439 mg/dL, Uric Acid 3.4-7.7 mg/dL and Total Proteins 6.63-8.03 g/L. Conclusions. A panel of RIs for locally-relevant biochemical parameters has been established. When comparing these results with other studies and those reported by reagent manufacturers, some differences were observed. This study thus contributes to increase the reliability in the interpretation of laboratory results and therefore to the clinical management of patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Reference intervals of biochemical parameters in Chilean adults

Letelier,

Acuña,

Garrido

et al. 2024

J Med Biochemistry

View full text Add to dashboard Cite

show abstract

Growth Hormone Deficiency: Diagnostic Principles and Practice

Ranke¹

2011

Diagnostics of Endocrine Function in Children and Adolescents

View full text Add to dashboard Cite

Growth hormone deficiency (GHD) by and large involves a wide range of disorders, including an impairment in GH secretion and/or a reduced impact of GH (table 1) [1]. It has been proposed that GH and IGF-1 are analogous to other endocrine systems in that they are interconnected, with GH being the regulatory hormone and IGF-1 the hormone acting primarily. A distinction is thus made between 'primary IGF deficiency' , which involves IGF-1 impairment but normal GH secretion and action, whereas 'secondary IGF deficiency' is a state in which IGF-1 is impaired due to irregularities in GH secretion [2]. These disorders are diagnosed via a combination of diagnostic tools [see also chapters by Blum and Albertsson-Wikland, this vol.]. In addition, imaging techniques and molecular genetic methods [see chapter by Pandey and Mullis, this vol.] can be applied to confirm and/or specify the diagnosis. More specifically, GHD is characterized by GH secretion levels that are below those for age-and sex-matched norms. In a broader sense, GHD is the clinical disorder resulting from the impaired secretion or action of GH in an individual. The first task in the diagnostic procedure should thus be to establish whether or not the clinical presentation of an individual corresponds with the situation of impaired GH secretion or action. If this is plausible, evidence must be sought, in a second step, for an impairment in GH secretion (or action). The difficulty in associating an individual's anthropometrical and biochemical phenotype with GH impairment is partly related to the fact that the phenotype may vary, depending on age and severity, as well as according to the duration of GH impairment at the time the patient presents. Moreover, certain signs or symptoms typical for GHD are also attributable to other causes. A combination of typical signs could thus be more helpful than a single characteristic specific to GH impairment. Finally, it must be mentioned that the empirical basis used to make a causal association between the quantitative deviation of anthropometrical/biochemical signs and a measurable degree of GH impairment is very narrow.

show abstract

Valores de referencia para proteína transportadora de hormona de crecimiento en una población pediátrica normal

Cited by 2 publications

References 0 publications

Reference intervals of biochemical parameters in Chilean adults

Reference intervals of biochemical parameters in Chilean adults

Growth Hormone Deficiency: Diagnostic Principles and Practice

Contact Info

Product

Resources

About